Objective
The programme aims to assess the environmental impact (if any) of the use of live recombinant virus vaccines. The host and tissue tropism of the recombinant vaccines will be determined and compared to those of the parent viruses. Possible evolution of an altered vaccine, following recombination of the recombinant vaccine and wild type viruses present in the environment, will be assessed.
Initial project objectives include:
construction of the different recombinant viruses based on capripox, Aujeszky's disease, and fowl pox virus;
construction of vectors to assess recombination between fowl pox virus and vaccinia virus;
recombination in vivo of wild type adenovirus (ADV) and modified ADV and of cowpox and vaccinia virus;
sera and tissue collection and screening for ecological surveys;
pathogenesis of cowpox in mammals.
Work to date has resulted in the construction of most of the recombinant viruses and construction of the vectors.
The virulence of the worst case recombinant virus NIA-3 gX E1 was compared with that of the virulent parent virus NIA-3 gX. 5 of the 3 week old specific pathogen free (SPF) piglets were infected intra-nasally with 10{5} pfu of the parent virus NIA-3 gX. and the recombinant virus NIA-3 gX E1. Preliminary findings indicate that both of the viruses cause sever and typical Aujeszky's disease and death. Three out of five died after inoculation with the recombinant and five out of five died after inoculation with the parent virus. Thus it appears that the worst case recombinant virus will not result in increased virulence of the virus in the field.
Sera samples have been collected from wild mammals for analysis for the presence of orthopoxvirus antibodies. Sera samples have also been collected from domestic animals in Continental Europe. These will be tested for the presence of antibodies to capripox or capripox related viruses. Samples from human and domestic animals with suspected cowpox have been screened. A further 14 strains of cowpox virus have been isolated, thus identifying geographical regions in which wild rodents will be sampled in an attempt to identify the reservoir host of the virus.
The project is continuing.
The development of recombinant vaccines has made rapid progress in the last few years. Environmental aspects related to the use of such vaccines are unknown and the safety regulations for the use of such vaccines are largely undefined. This collaborative programme aims to address the following aspects.
To provide a scientific basis to be able to predict and evaluate potential environmental problems involved in the use of these vaccines by identifying the factors that are pertinent to the safety of the vaccines, and developing the techniques necessary to evaluate the effect of the use of these vaccines prior to release.
Identification of factors that must be considered to develop the techniques necessary to evaluate the effect of the use of these vaccines prior to release.
To provide a basis for the establishment European and international legislation for the use of the recombinant vaccines. Studies will concentrate on possible changes in tissue and host tropism of the vector system as a result of the expression of the heterologous genes, and any associated pathogenic alterations. In addition we will study the possibility of recombination between live recombinant vaccine virus and wild type field virus. The virus vector systems to be studied, capripoxvirus, fowlpoxvirus, orthopoxvirus and herpes virus are expected to be applied in the field in the near future as multivalent recombinant vaccines.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- natural sciences biological sciences microbiology virology
- agricultural sciences animal and dairy science domestic animals
- medical and health sciences basic medicine pharmacology and pharmacy pharmaceutical drugs vaccines
- natural sciences biological sciences zoology mammalogy
You need to log in or register to use this function
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Data not available
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Data not available
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Coordinator
GU24 0NF WOKING
United Kingdom
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.